^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Non Small Cell Lung Cancer

    Related cancers:
    1d
    Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (clinicaltrials.gov)
    P3, N=870, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jul 2026 --> May 2027 | Trial completion date: Feb 2027 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    1d
    AMT-116 in Combination With Ivosidan in Patients With Lung Cancer (clinicaltrials.gov)
    P1/2, N=118, Not yet recruiting, Multitude Therapeutics Inc.
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR wild-type • ALK fusion
    |
    Yidafan (ivonescimab)
    1d
    Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) (clinicaltrials.gov)
    P1, N=145, Active, not recruiting, Daiichi Sankyo | Trial completion date: Apr 2026 --> Dec 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-L2 (Programmed Cell Death 1 Ligand 2) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan-dlnk)
    1d
    IOV-COM-202: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=225, Terminated, Iovance Biotherapeutics, Inc. | Trial completion date: Aug 2029 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Aug 2029 --> Feb 2026; After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.
    Trial completion date • Trial termination • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw) • Amtagvi (lifileucel) • relatlimab (BMS-986016) • LN-145 • LN-145-S1
    2d
    YL202-INT-101-01: A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative
    |
    BNT326
    2d
    RTOG 1308: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer (clinicaltrials.gov)
    P3, N=330, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    2d
    Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Northwestern University | Trial completion date: Mar 2026 --> Aug 2031 | Trial primary completion date: Feb 2026 --> Aug 2028
    Trial completion date • Trial primary completion date
    2d
    A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2027 --> Mar 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    2d
    DARANIVOVAX: Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=54, Recruiting, Georgetown University | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2d
    NCI-2015-01505: Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=124, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Feb 2026 | Trial primary completion date: Sep 2026 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    2d
    Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Apr 2026 --> Mar 2027
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • Zykadia (ceritinib)
    2d
    M70103: A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Wuhan YZY Biopharma Co., Ltd. | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • M701